Journal
EPIGENOMICS
Volume 8, Issue 1, Pages 55-66Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi.15.97
Keywords
B-cell neoplasms; DNA methylation; lymphoma; peripheral blood methylation
Categories
Funding
- VicHealth
- Cancer Council Victoria
- Australian NHMRC [209057, 251553, 504711]
Ask authors/readers for more resources
Aim: To examine whether peripheral blood methylation is associated with risk of developing mature B-cell neoplasms (MBCNs). Materials & methods: We conducted a case-control study nested within a large prospective cohort. Peripheral blood was collected from healthy participants. Cases of MBCN were identified by linkage to cancer registries. Methylation was measured using the Infinium (R) HumanMethylation450. Results: During a median of 10.6-year follow-up, 438 MBCN cases were evaluated. Global hypomethylation was associated with increased risk of MBCN (odds ratio: 2.27, [95% CI: 1.59-3.25]). Within high CpG promoter regions, hypermethylation was associated with increased risk (odds ratio: 1.76 [95% CI: 1.25-2.48]). Promoter hypermethylation was observed in HOXA9 and CDH1 genes. Conclusion: Aberrant global DNA methylation is detectable in peripheral blood collected years before diagnosis and is associated with increased risk of MBCN, suggesting changes to DNA methylation are an early event in MBCN development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available